Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
207940KOSPI·May 23, 2025
CDMO and biosimilar businesses to be separated
Mirae Asset Securities published a company analysis report on Samsung Biologics (207940) titled "CDMO and biosimilar businesses to be separated".
Summary
Covers Samsung Biologics (207940).
Covered stock
More on 207940
Order concerns ease as growth drivers expandMirae Asset Securities · Jul 27, 2026Initiating Coverage: Unwavering Growth, Time to Build ConvictionKB Securities · May 27, 2026Fair value of W106trMirae Asset Securities · Nov 24, 2025Spin-off likely to unlock additional valueMirae Asset Securities · Oct 29, 2025Positioning for the next leg of growthMirae Asset Securities · Jul 25, 2025Earnings surpass heightened expectationsMirae Asset Securities · Apr 24, 2025Globally leading CDMO in terms of growth and marginsMirae Asset Securities · Jan 23, 2025